BioVersys raises €8.7M Series C round

5 January 2023· Basel, Switzerland· health, biotech, drug_discovery, antimicrobial_resistance, b2b

To support the clinical development of BV100, a potential breakthrough hospital antibiotic targeting the most drug-resistant bacterial pathogen, Acinetobacter baumannii.

Investors

LeadAMR Action Fund

About BioVersys

Stage

Series C

Headquarters

Basel, Switzerland

Founded

2008

Team Size

21–50

Sectors

healthbiotechdrug_discoveryantimicrobial_resistanceb2b

http://www.bioversys.com/

Source: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGprBew2NJXM_9ttznp3SJPqGwoc3FMX-Z9VOzXJvsfCo3ON_feutiYKRorxj2F_nEwewKdiIUsZYCCwx-F04DN1mhf9JzkVniOruSf0JOJ8oSFmzQ1v4u9Y6eQgvyhbJe65jcP3E6rKic-mzVcOsDho11_PD3Nvwv2qNb_AZgytjuZ9YBqKAbmDOHZfG4GF3iogXOs1yCSTPKUCjg98g5XoTW1Ojyog32kHnuCcHFqNjO3VUB5eVM==, https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFcgZ_j-0uixSqX52CmO5jTw4SVxLpDO_ce6aFnkLpz4zQqRfAJn31wD_bjY43THKGvoh2W2gCCvqDz5DsaxcZv9sm3JIg4DpLiA5Dl_ySH4-PhOVR5dlq4NqyA0kosKjwd8W3tHZ1sVkvNXaH4cF_3I1ZOJ55K-gqbo0zfzk_k4pfWUda6rxYe4GRPEGObcskwhw==, https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF4YSfHxCTSYO1iH-40DvbclqOZIQIGxBU-f6VSm4rw52lV1no3SxDUqa3_hXKkinwRyv44GhoVwqPohe5BN9djjNqpMX4H81bYAF0yI_SqRHbZBX63GTqb9zHHS84ZFoCrgtQiQ_sFxa7Once1Eghf7h1m9lcT7y2Uj5k4WYJQ3jLaLM22zkNNVYXhbcai4VRZ